A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Recruiting

Phase 3

MK-8527A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT07044297

Conditions

Human Immunodeficiency Virus (HIV)

HIV Pre-Exposure Prophylaxis

Eligibility Criteria

Sex: All

Age: 16+

Healthy Volunteers: Accepted

Interventions

MK-8527

FTC/TDF

Placebo to MK-8527

Placebo to FTC/TDF

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-10. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2026-02-27.